Twist Bioscience Corporation (NASDAQ:TWST) was founded on February 4, 2013, headquartered in San Francisco, California, USA, with 221 full-time employees (6/30/2018). It is a leading and rapidly growing synthetic biology company that has developed Destructive DNA synthesis platform to realize the industrialization of biological engineering.
Twist Bioscience Corp. (TWST):
Twist Bioscience is a San Francisco-based company that produces synthetic DNA for customers in the biotechnology industry. Twist was founded in 2013 by Emily Leproust, Bill Peck and Bill Banyai, the first two of whom were previously responsible for Agilent Technologies ’ DNA synthesis technology.
The core of the Twist Bioscience platform is a proprietary technology that creates a new method of making synthetic DNA by “writing” DNA on a silicon chip. The company combines this technology with proprietary software, scalable business infrastructure and e-commerce platform to create an integrated technology platform that enables it to achieve a high level of quality, precision, and accuracy at a much lower cost than its competitors. Automation and manufacturing volume.
Twist Bioscience has developed proprietary microplate equipment, based in part on the lithography technology used to manufacture semiconductors in the Silicon Valley computer industry, and advanced liquid handling robotics for building DNA in microplates. A typical microplate has 96 wells, the size of which is equivalent to two decks of playing cards; Twist’s chip is the size of a postage stamp, with 96 wells, each with 96 wells.
In 2016, Twist acquired the Israeli software company Genome Compiler, which sold software for designing synthetic DNA, and then signed a cooperation agreement with a similar software company Desktop Genetics. Each transaction provides a way for customers to order Twist’s DNA directly from the DNA design software.
Twist Bioscience sells genes, gene fragments and oligonucleotides to customers. Sales of genes, gene fragments and oligonucleotides are used in basic research, drug development (for example, creating monoclonal antibody drug candidates), and industrial biotechnology (for example, Hope to find better enzymes to generate biofuel companies)) and agricultural biotechnology.
Microsoft also purchased DNA for research on DNA digital data storage.
Twist Bioscience Corp. (TWST) investment:
Twist Bioscience Corporation (NASDAQ:TWST) submitted its IPO prospectus on 10/3/2018, and listed on NASDAQ on 10/31/2018. The issue price is US$14.00, 5 million shares are issued, and 70 million US dollars are raised. JP Morgan / Cowen underwriting.